Comparative Pharmacology
Head-to-head clinical analysis: CEFOTETAN versus CEFPODOXIME PROXETIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOTETAN versus CEFPODOXIME PROXETIL.
CEFOTETAN vs CEFPODOXIME PROXETIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and disrupting peptidoglycan cross-linking.
Cefpodoxime proxetil is a prodrug that is de-esterified in vivo to cefpodoxime, a third-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and disrupting peptidoglycan cross-linking, leading to cell lysis. It has broad-spectrum activity against Gram-positive and Gram-negative bacteria.
1 to 2 g intravenously or intramuscularly every 12 hours. For severe infections, up to 2 g every 12 hours for 5-10 days.
200 mg orally every 12 hours
None Documented
None Documented
Clinical Note
moderateCefotetan + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefotetan."
Clinical Note
moderateCefotetan + Ethanol
"The risk or severity of adverse effects can be increased when Cefotetan is combined with Ethanol."
Clinical Note
moderateCefotetan + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefotetan."
Clinical Note
moderateCefotetan + Carbocisteine
3-4.5 hours (6-8 hours in renal impairment).
Terminal elimination half-life of cefpodoxime is 2.2-2.8 hours in healthy adults; prolonged to 5.9-9.8 hours in moderate renal impairment (CrCl 10-30 mL/min) and up to 13-14 hours in severe impairment (CrCl <10 mL/min).
Renal (80-90% unchanged), biliary (small amount, up to 20% in bile), fecal (<5%).
Renal excretion of unchanged drug (29-33%) and fecal/biliary elimination of inactive metabolites; 80% of radiolabeled dose recovered in urine and feces over 8 days.
Category C
Category A/B
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The risk or severity of adverse effects can be increased when Cefotetan is combined with Carbocisteine."